{
    "1R3.F": {
        "short_name": "IZOTROPIC CORP.",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "1UB.F": {
        "short_name": "COGNETIVITY NEUROC. LTD",
        "long_name": "Cognetivity Neurosciences Ltd.",
        "summary": "Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially allowing early diagnosis of dementia. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "20B.F": {
        "short_name": "BIOMARK DIAGNOSTICS INC.",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. It also has a collaborative research and development agreement with Phytronix Technologies Inc. to advance the development of early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption technology. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "3D0A.F": {
        "short_name": "TELO GENOMICS CORP. O.N.",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "61N1.F": {
        "short_name": "STAGEZERO LIFE SCIENC.",
        "long_name": "StageZero Life Sciences Ltd.",
        "summary": "StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "75J.F": {
        "short_name": "LEVELJUMP HEALTHCARE CORP",
        "long_name": "Leveljump Healthcare Corp.",
        "summary": "Leveljump Healthcare Corp. operates as a medical diagnostic imaging company. It provides teleradiology services to its client hospitals and imaging centers. The company is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "8VP1.F": {
        "short_name": "AVRICORE HEALTH INC.",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "AVCR.V": {
        "short_name": "AVRICORE HEALTH INC",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "AVCRF": {
        "short_name": "AVRICORE HEALTH INC",
        "long_name": "Avricore Health Inc.",
        "summary": "Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. In addition, it offers Corozon Platform, which consists of Corozon Academy that provides practical professional education to community pharmacists; and Corozon Hardware, an e-commerce portal that allows pharmacists to order point-of-care diagnostic devices and supplies. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "BMKDF": {
        "short_name": "BIOMARK DIAGNOSTICS INC",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. It also has a collaborative research and development agreement with Phytronix Technologies Inc. to advance the development of early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption technology. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "BUX.CN": {
        "short_name": "BioMarkDiagnos",
        "long_name": "Biomark Diagnostics Inc",
        "summary": "Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a collaboration with the University of Maryland School of Medicine related to the discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity. It also has a collaborative research and development agreement with Phytronix Technologies Inc. to advance the development of early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption technology. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "CGN.CN": {
        "short_name": "CognetivityNeu",
        "long_name": "Cognetivity Neurosciences Ltd.",
        "summary": "Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially allowing early diagnosis of dementia. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "CGNH": {
        "short_name": "CARDIOGENICS HOLDINGS INC",
        "long_name": "CardioGenics Holdings Inc",
        "summary": "CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "CGNSF": {
        "short_name": "COGNETIVITY NEUROSCIENCES LTD",
        "long_name": "Cognetivity Neurosciences Ltd.",
        "summary": "Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical and commercial environments for potentially allowing early diagnosis of dementia. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "EDT.TO": {
        "short_name": "SPECTRAL MEDICAL INC",
        "long_name": "Spectral Medical Inc.",
        "summary": "Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "EDTXF": {
        "short_name": "SPECTRAL MEDICAL INC",
        "long_name": "Spectral Medical Inc.",
        "summary": "Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "EIY2.F": {
        "short_name": "RELAY MEDICAL",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company provides Fionet, a mobile testing and tracking platform, which combines handheld devices linked to online AI-powered cloud, automating frontline testing, and capturing test results for tracking; HemoPalm, a blood analyzer and single-use cartridge that provides enterprise solution for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an user experience -centric system design to improve management and identification of medications. It offers techno-commercial leadership and support services for the venture that pursue technology opportunities in the medicinal cannabis, agrotechnology, and other related industries. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "GNWSF": {
        "short_name": "STAGEZERO LIFE SCIENCES LTD",
        "long_name": "StageZero Life Sciences Ltd.",
        "summary": "StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "IZO.CN": {
        "short_name": "IzotropicCorp",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "IZOZF": {
        "short_name": "IZOTROPIC CORPORATION",
        "long_name": "Izotropic Corporation",
        "summary": "Izotropic Corporation, a research and development company, commercializes diagnostic products for breast cancer. It develops and commercializes next generation 3D breast CT imaging technology for the earlier detection, diagnosis, and treatment of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Surrey"
    },
    "JMPHF": {
        "short_name": "LEVELJUMP HEALTHCARE CORP",
        "long_name": "Leveljump Healthcare Corp.",
        "summary": "Leveljump Healthcare Corp. operates as a medical diagnostic imaging company. It provides teleradiology services to its client hospitals and imaging centers. The company is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "JUMP.V": {
        "short_name": "LEVELJUMP HEALTHCARE CORP",
        "long_name": "Leveljump Healthcare Corp.",
        "summary": "Leveljump Healthcare Corp. operates as a medical diagnostic imaging company. It provides teleradiology services to its client hospitals and imaging centers. The company is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "MBI-H.V": {
        "short_name": "MED BIOGENE INC",
        "long_name": "Med BioGene Inc.",
        "summary": "Med BioGene Inc. does not have significant operations. Previously, it was engaged in the life science business with a focus on the development and commercialization of genomic-based clinical tests for non-small-cell lung cancer. The company focuses on the commercialization of technologies in various industrial sectors. Med BioGene Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "RELA.CN": {
        "short_name": "RelayMedCorp",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company provides Fionet, a mobile testing and tracking platform, which combines handheld devices linked to online AI-powered cloud, automating frontline testing, and capturing test results for tracking; HemoPalm, a blood analyzer and single-use cartridge that provides enterprise solution for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an user experience -centric system design to improve management and identification of medications. It offers techno-commercial leadership and support services for the venture that pursue technology opportunities in the medicinal cannabis, agrotechnology, and other related industries. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "RYMDF": {
        "short_name": "RELAY MEDICAL CORP",
        "long_name": "Relay Medical Corp.",
        "summary": "Relay Medical Corp. develops and sells products in the medical device, consumer health, and health IT industries. The company provides Fionet, a mobile testing and tracking platform, which combines handheld devices linked to online AI-powered cloud, automating frontline testing, and capturing test results for tracking; HemoPalm, a blood analyzer and single-use cartridge that provides enterprise solution for point-of-care blood gas and CO-oximetry testing; and Pharmatrac, an user experience -centric system design to improve management and identification of medications. It offers techno-commercial leadership and support services for the venture that pursue technology opportunities in the medicinal cannabis, agrotechnology, and other related industries. The company was formerly known as ChroMedX Corp. and changed its name to Relay Medical Corp. in June 2018. Relay Medical Corp. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SCRN.CN": {
        "short_name": "ScreenProSec",
        "long_name": "ScreenPro Security Inc.",
        "summary": "ScreenPro Security Ltd. provides Covid-19 testing solutions to governments and corporations. The company was incorporated in 2020 and is headquartered in British Columbia, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "SD4.F": {
        "short_name": "SPECTRAL MEDICAL",
        "long_name": "Spectral Medical Inc.",
        "summary": "Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SQD.V": {
        "short_name": "SQI DIAGNOSTICS INC.",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a precision medicine company, discovers, develops, produces, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company provides advanced diagnostics targeting organ transplant, autoimmune disease, and serological testing. It also offers TOR-dx, a lung panel test, which enables surgeon to assess the health of donor's lung; and COVID-19 at-home antibody test kit, and the RALI-Dx and RALI-fast point-of care tests to triage COVID-19 patients for respiratory distress. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SQIDF": {
        "short_name": "SQI DIAGNOSTICS INC",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a precision medicine company, discovers, develops, produces, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company provides advanced diagnostics targeting organ transplant, autoimmune disease, and serological testing. It also offers TOR-dx, a lung panel test, which enables surgeon to assess the health of donor's lung; and COVID-19 at-home antibody test kit, and the RALI-Dx and RALI-fast point-of care tests to triage COVID-19 patients for respiratory distress. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SZLS.TO": {
        "short_name": "STAGEZERO LIFE SCIENCES LTD",
        "long_name": "StageZero Life Sciences Ltd.",
        "summary": "StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "TDSGF": {
        "short_name": "TELO GENOMICS CORP",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "TELO.V": {
        "short_name": "TELO GENOMICS CORP",
        "long_name": "Telo Genomics Corp.",
        "summary": "Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "XSQ.F": {
        "short_name": "SQI DIAGNOSTICS INC.",
        "long_name": "SQI Diagnostics Inc.",
        "summary": "SQI Diagnostics Inc., a precision medicine company, discovers, develops, produces, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company provides advanced diagnostics targeting organ transplant, autoimmune disease, and serological testing. It also offers TOR-dx, a lung panel test, which enables surgeon to assess the health of donor's lung; and COVID-19 at-home antibody test kit, and the RALI-Dx and RALI-fast point-of care tests to triage COVID-19 patients for respiratory distress. SQI Diagnostics Inc. was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    }
}